Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

OCTOBER 16, 2012

Pharmatest became preferred provider of Valirx

The Turku-based company Pharmatest Services Ltd (Pharmatest) has signed a Master Service Agreement with the London AIM-listed cancer drug development company Valirx Plc (Valirx). The agreement makes Pharmatest preferred provider of preclinical efficacy testing services for Valirx in its cancer drug development programs.

Pharmatest offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Valirx is developing new cancer drugs and has tested their compounds in several models of Pharmatest. After about one year of customer relationship Valirx decided to sign a long-term Master Service Agreement with Pharmatest that gives Pharmatest preferred provider status for the services that it offers.

Valirx expects that the agreement will help them especially in selecting the most effective compounds from their GeneICE program and confirming correct indications for the selected compounds for planning subsequent clinical trials. Satu Vainikka, CEO of Valirx says: “We have been very pleased about the quality of the services that Pharmatest provides and we are convinced that this partnership will significantly benefit our cancer drug development programs.”

Jussi Halleen, CEO of Pharmatest comments: “We are very happy to sign this agreement with Valirx to follow our preferred provider partnership with Bayer Healthcare that was signed in 2010. These partnerships show that we are on the right track in developing our services.”

The press release can be found here (in English) or here (in Finnish).